Roche lung cancer drug reduces by 76% risk of recurrence or death

The findings could give patients with early-stage ALK-positive cancers an alternative to chemotherapy.

October 24, 2023 Check out STAT+

Sponsored By

Andrew Joseph/STAT STAT+ | Roche drug slashes recurrence, death risk in lung cancer that afflicts younger patients Alecensa lowered the risk of recurrence or death in a type of lung cancer that typically afflicts younger patients. By Andrew Joseph STAT+ | Results on Novartis prostate cancer therapy could expand its use The Phase 3 data amount to another win for cancer therapies designed to deliver radiation directly to tumor cells. By Andrew Joseph STAT+ | Data on AstraZeneca cancer drug allay safety concerns but treatment still faces questions On Monday, data presented from a trial of the drug in advanced non-small cell lung cancer provided at least a fuller look. By Andrew Joseph Andrew Joseph/STAT STAT+ | In lung cancer, J&J data amount to latest salvo against AstraZeneca A competition has been brewing between Johnson & Johnson and AstraZeneca to gain an edge in the market for targeted lung cancer treatments. By Andrew Joseph STAT+ | Study on Amgen's 'bispecific' immunotherapy could lead to approval in small cell lung cancer The drug generated strong response rates in patients with advanced small cell lung cancer, results that could lead to approval. By Andrew Joseph

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser